Immunogenicity of COVID-19 vaccines in lung cancer patients.

Immunogenicity of COVID-19 vaccines in lung cancer patients.

Publication date: Oct 01, 2023

Patients with lung cancer are at increased risk of SARS-CoV-2 infection and severe complications from COVID-19, but information on the efficacy of anti-SARS-CoV-2 vaccine in these patients is scarce. We aimed at evaluating the safety and immunogenicity of COVID-19 vaccines in this population. The prospective, nationwide SOLID substudy, enrolled adults with lung cancer who were fully vaccinated against COVID-19. Serum anti-SARS-CoV-2 IgG antibody levels were quantitatively assessed two weeks and six months after receipt of the last dose using a chemiluminescent microparticle immunoassay. Multivariate odds ratios for the association between demographic and clinical factors and seronegativity after vaccination were estimated. 1973 lung cancer patients were enrolled. Most patients had stage IV disease (66%) and were receiving active cancer treatment (82. 7%). No significant differences were found in the probability of being seronegative for anti-SARS-CoV-2 IgG antibodies after full vaccination between patients who were receiving active cancer treatment and those who were not (p = 0. 396). The administration of immunotherapy or oral targeted therapy and immunization with mRNA-1273 COVID-19 vaccine were factors independently associated with increased odds of being seropositive after vaccination. From all patients, 1405 received the second dose of vaccine and high levels of antibody titers were observed in 93. 6% of patients two weeks after second dose. At six months, multivariate logistic regression analysis showed that performance status ≥ 2 was independently associated with a higher probability of being seronegative after full vaccination with an OR 4. 15. On the other hand, received chemotherapy or oral target therapy and vaccination with mRNA-1273 were a factor independently associated with lower odds of being seronegative after full vaccination with an OR 0. 52, 0. 37 and 0. 34, respectively. Lung cancer patients can safely achieve a strong immune response against SARS-CoV-2 after full vaccination, regardless of the cancer treatment received. NCT04407143.

Concepts Keywords
Chemotherapy COVID-19
Nct04407143 Immune response
Severe Lung cancer
Stage Neutralizing antibodies
Vaccinated SARS-CoV-2


Type Source Name
disease MESH COVID-19
disease MESH lung cancer
pathway REACTOME SARS-CoV-2 Infection
disease MESH complications
disease VO vaccine
disease VO population
disease VO vaccinated
disease VO dose
disease VO vaccination
disease MESH cancer
disease VO immunization
disease VO COVID-19 vaccine
disease IDO immune response

Original Article

(Visited 1 times, 1 visits today)